Comparative Pharmacology
Head-to-head clinical analysis: OZURDEX versus PREDSULFAIR II.
Peer-Reviewed Evidence
Head-to-head clinical analysis: OZURDEX versus PREDSULFAIR II.
OZURDEX vs PREDSULFAIR II
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dexamethasone, a potent corticosteroid, reduces inflammation by inhibiting multiple inflammatory cytokines including prostaglandins, leukotrienes, and interleukins. It suppresses the migration of polymorphonuclear leukocytes and reverses increased capillary permeability. The mechanism involves binding to the glucocorticoid receptor, leading to regulation of gene expression that reduces production of inflammatory mediators.
Prednisolone is a corticosteroid with glucocorticoid and mineralocorticoid activity. It binds to the glucocorticoid receptor, leading to modulation of gene expression and suppression of inflammatory mediators. Sulfonamide component provides bacteriostatic action via inhibition of dihydropteroate synthase in bacterial folate synthesis.
Single intravitreal implant of 0.7 mg (dexamethasone 700 mcg) in the affected eye; repeat dosing no sooner than 3 months after the prior implant.
1-2 drops into the affected eye(s) every 4-6 hours; not to exceed 6 doses per day.
None Documented
None Documented
In the vitreous humor, the half-life is approximately 5-7 months following intravitreal implant administration. Systemic half-life is negligible due to low systemic exposure.
Terminal elimination half-life of prednisolone (active moiety): 2.1-3.5 hours; clinical context: duration of HPA axis suppression exceeds plasma half-life (12-36 hours).
Primarily hepatic metabolism via CYP3A4; metabolites excreted in feces (≈70%) and urine (≈30%). Less than 1% excreted as unchanged drug.
Renal: 70-80% (30-50% as unchanged prednisolone, 20-30% as prednisone and inactive metabolites); Biliary/Fecal: 15-20%
Category C
Category C
Ophthalmic Corticosteroid
Ophthalmic Corticosteroid/Sulfonamide Combination